Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Sold by Total Clarity Wealth Management Inc.

Total Clarity Wealth Management Inc. trimmed its holdings in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) by 30.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,085 shares of the biotechnology company’s stock after selling 2,674 shares during the quarter. Total Clarity Wealth Management Inc.’s holdings in Viking Therapeutics were worth $245,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Signaturefd LLC grew its stake in shares of Viking Therapeutics by 16.2% in the third quarter. Signaturefd LLC now owns 1,351 shares of the biotechnology company’s stock valued at $86,000 after buying an additional 188 shares in the last quarter. Stone House Investment Management LLC boosted its holdings in Viking Therapeutics by 66.7% during the 3rd quarter. Stone House Investment Management LLC now owns 500 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 200 shares during the period. Keudell Morrison Wealth Management grew its position in Viking Therapeutics by 5.9% in the 3rd quarter. Keudell Morrison Wealth Management now owns 4,306 shares of the biotechnology company’s stock valued at $273,000 after acquiring an additional 241 shares in the last quarter. GAMMA Investing LLC increased its stake in Viking Therapeutics by 124.6% during the third quarter. GAMMA Investing LLC now owns 438 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 243 shares during the period. Finally, Massmutual Trust Co. FSB ADV lifted its position in shares of Viking Therapeutics by 84.3% during the third quarter. Massmutual Trust Co. FSB ADV now owns 553 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 253 shares in the last quarter. 76.03% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. StockNews.com raised shares of Viking Therapeutics to a “sell” rating in a research note on Tuesday, October 15th. B. Riley began coverage on Viking Therapeutics in a research report on Friday, November 22nd. They set a “buy” rating and a $109.00 price objective on the stock. Piper Sandler began coverage on Viking Therapeutics in a research note on Monday, December 2nd. They set an “overweight” rating and a $74.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $102.00 price target on shares of Viking Therapeutics in a research report on Friday, January 17th. Finally, William Blair reissued an “outperform” rating on shares of Viking Therapeutics in a research report on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating, eleven have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Viking Therapeutics presently has a consensus rating of “Buy” and an average target price of $106.75.

Viking Therapeutics Trading Down 2.8 %

Shares of NASDAQ:VKTX opened at $32.75 on Friday. Viking Therapeutics, Inc. has a 12 month low of $22.51 and a 12 month high of $99.41. The company’s fifty day moving average price is $42.17 and its 200 day moving average price is $54.54.

Insiders Place Their Bets

In other news, CEO Brian Lian sold 194,490 shares of Viking Therapeutics stock in a transaction on Monday, January 6th. The shares were sold at an average price of $42.75, for a total value of $8,314,447.50. Following the transaction, the chief executive officer now directly owns 2,366,570 shares of the company’s stock, valued at $101,170,867.50. The trade was a 7.59 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Greg Zante sold 50,309 shares of the firm’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $42.75, for a total transaction of $2,150,709.75. Following the transaction, the chief financial officer now directly owns 165,259 shares in the company, valued at $7,064,822.25. The trade was a 23.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 301,014 shares of company stock valued at $12,920,189. 4.70% of the stock is currently owned by insiders.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.